Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Fish oil may ease side effects of stem cell transplants in kids

NCT ID NCT02512718

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 34 times

Summary

This early-stage trial tested whether a fish oil-based fat emulsion is safe and tolerable for 20 children undergoing stem cell transplants for cancer or blood disorders. The fish oil emulsion was compared to the standard soybean oil emulsion. The goal was to see if the omega-3-rich fish oil could reduce infections and other complications, providing data for a larger future study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

fish oil lipid emulsion (Omegaven)

What this could lead to

If it works, this could point toward a safer way to provide nutrition during stem cell transplants, potentially reducing infections and side effects.

What could go wrong

This is a very early Phase 1 pilot study with only 20 children, so results may not be conclusive. The fish oil emulsion could still cause side effects or not show clear benefits.

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.